Stock Data
$1.87 (1.34%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
MEDICAL DEVICES
Insulet Corporation specializes in innovative insulin delivery systems for those with insulin-dependent diabetes. Its flagship Omnipod platform offers a range of products, including the Omnipod 5, which integrates with continuous glucose monitors for automated insulin delivery, and the Omnipod DASH, a smartphone-like device managing insulin delivery with ease. Additionally, the Omnipod GO provides a simple, wearable insulin delivery option. With a focus on accessibility, Insulet sells its products globally through distributors, pharmacies, and direct sales, aiming to improve the lives of people with diabetes around the world. Founded in 2000, the company is based in Acton, Massachusetts.
International Omnipod revenue jumped 35.5% to $251.8 million, enough to cover a slower ramp in U.S. type 2 diabetes and still clear both consensus lines. Management cut full-year U.S. Omnipod growth guidance to 17%-19% from 20%-22% while lifting adjusted EPS growth above 30%, so the type 2 recalibration reflects mix.
28 Articles
Our top personal finance-related articles today. Your wallet will thank you later.
